Ntumba, P.N.; Akilimali, P.Z. Evaluation of Mass Drug Administration Coverage for Lymphatic Filariasis in the Lukonga Health Zone in 2022. Trop. Med. Infect. Dis.2024, 9, 156.
Ntumba, P.N.; Akilimali, P.Z. Evaluation of Mass Drug Administration Coverage for Lymphatic Filariasis in the Lukonga Health Zone in 2022. Trop. Med. Infect. Dis. 2024, 9, 156.
Ntumba, P.N.; Akilimali, P.Z. Evaluation of Mass Drug Administration Coverage for Lymphatic Filariasis in the Lukonga Health Zone in 2022. Trop. Med. Infect. Dis.2024, 9, 156.
Ntumba, P.N.; Akilimali, P.Z. Evaluation of Mass Drug Administration Coverage for Lymphatic Filariasis in the Lukonga Health Zone in 2022. Trop. Med. Infect. Dis. 2024, 9, 156.
Abstract
Abstract: (1) Background and rationale: To validate the reported therapeutic coverage, a lymphatic filariasis post-mass drug administration (MDA) campaign survey was conducted in the Lukonga health zone from 10 June to 15 July 2023. (2) Materials and methods: This was a descriptive, cross-sectional study conducted at the community level in 30 villages in the Lukonga health zone from 10 June to 15 July 2023. The study population included all individuals from the visited com-munities. The study variables included age, sex, drug use (ivermectin + albendazole), adverse events, and adherence to MDA guidelines for supervised drug use. Questionnaires were administered on Android phones using the SurveyCTO platform. Stata version 17 was used for data analysis. (3) Results: Of the 1092 respondents, 54.8% were female and one-third were between the ages of 5 and 14. Two-thirds of the households surveyed, or 64%, had more than six people living in them, and 1031 individuals, or 94%, reported being present during the community mass drug distribution. Notably, 678 individuals, or 66%, reported taking the drugs offered, and 66.4% of those who took the drugs reported doing so in the presence of drug distributors. Thus, the survey coverage was 65.7% [95% CI: 62.9–68.7]. The results of this study show that the survey coverage was above the 65% threshold recommended by the WHO but below the 82.3% reported by the Lukonga health zone. The main reason for non-compliance was a fear of ivermectin-related side effects (47%). Supervised or directly observed treatment was not adhered to (66.4%). (4) Discussion and conclusions: Key challenges to further increase treatment coverage include assessing data quality, building capacity, motivating drug distributors, improving data reporting tools, proper recording by drug distributors, and ac-curate reporting on non-residents who take the drugs during the MDA. In addition, harmonization of the numerator for calculating drug coverage in the health zone is critical.
Keywords
lymphatic filariasis; therapeutic coverage; supervised treatment; mass treatment; preventive chemotherapy
Subject
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
